Mannose-capped lipoarabinomannan from Mycobacterium tuberculosis induces soluble tumor necrosis factor receptor production through tumor necrosis factor alpha-converting enzyme activation

Infection and Immunity

Volumn 80, Issue 11, 2012, Pages 3858-3868

  Richmond, Jillian M ^a,c   Duffy, Elizabeth R ^a   Lee, Jinhee ^b   Kaboli, Kavon ^a   Remick, Daniel G ^a   Kornfeld, Hardy ^b   Cruikshank, William W ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOARABINOMANNAN; MANNOSE; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; VIRULENCE FACTOR;

ADOLESCENT; ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL CELL WALL; BLOOD SAMPLING; CELL STIMULATION; CYTOKINE PRODUCTION; ENZYME ACTIVATION; FEMALE; HUMAN; LUNG LAVAGE; MALE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; TUBERCULOSIS;

ADAM PROTEINS; ANIMALS; ANTIGENS, BACTERIAL; CELLS, CULTURED; CYTOKINES; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; LIPOPOLYSACCHARIDES; MANNOSE; MICE; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84867613354     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00060-12     Document Type: Article

References (58)

1. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. 1992. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J. Exp. Med. 175:323-329.
2. Aggarwal BB. 2003. Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3:745-756.
3. Algood HMS, Lin PL, Flynn JL. 2005. Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin. Infect. Dis. 41(Suppl 3):S189 -S193. doi:10.1086/429994.
4. Amour A, et al. 1998. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. 435:39-44.
5. Balcewicz-Sablinska MK, Keane J, Kornfeld H, Remold HG. 1998. Pathogenic Mycobacterium tuberculosis evades apoptosis of host macrophages by release of TNF-R2, resulting in inactivation of TNF-alpha. J.Immunol. 161:2636 -2641.
6. Bean AG, et al. 1999. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J. Immunol. 162:3504 -3511.
7. Beatty WL, et al. 2000. Trafficking and release of mycobacterial lipids from infected macrophages. Traffic 1:235-247.
8. Black RA, et al. 2003. Substrate specificity and inducibility of TACE (tumour necrosis factor alpha-converting enzyme) revisited: the Ala-Val preference, and induced intrinsic activity. Biochem. Soc. Symp. 2003:39-52.
9. Black RA, et al. 1997. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385:729 -733.
10. Boehme C, et al. 2005. Detection of mycobacterial lipoarabinomannan with an antigen-capture ELISA in unprocessed urine of Tanzanian patients with suspected tuberculosis. Trans. R. Soc. Trop. Med. Hyg. 99:893-900.
11. Brennan FM, et al. 2008. Interleukin-10 regulates TNF-alpha-converting enzyme (TACE/ADAM-17) involving a TIMP-3 dependent and independent mechanism. Eur. J. Immunol. 38:1106 -1117.
12. Brou C, et al. 2000. A novel proteolytic cleavage involved in Notch signaling:the role of the disintegrin-metalloprotease TACE. Mol. Cell 5:207-216.
13. Chan J, Fan XD, Hunter SW, Brennan PJ, Bloom BR. 1991. Lipoarabinomannan,a possible virulence factor involved in persistence of Mycobacterium tuberculosis within macrophages. Infect. Immun. 59:1755-1761.
14. Chatterjee D, Khoo K-H. 1998. Mycobacterial lipoarabinomannan: an extraordinary lipoheteroglycan with profound physiological effects. Glycobiology 8:113-120.
15. Dahl KE, Shiratsuchi H, Hamilton BD, Ellner JJ, Toossi Z. 1996.Selective induction of transforming growth factor beta in human monocytes by lipoarabinomannan of Mycobacterium tuberculosis. Infect. Immun.64:399-405.
16. Dai H, Guzman J, Chen B, Costabel U. 2005. Production of soluble tumor necrosis factor receptors and tumor necrosis factor-alpha by alveolar macrophages in sarcoidosis and extrinsic allergic alveolitis. Chest 127:251-256.
17. DeForge LE, Kenney JS, Jones ML, Warren JS, Remick DG. 1992. Biphasic production of IL-8 in lipopolysaccharide (LPS)-stimulated human whole blood. Separation of LPS-and cytokine-stimulated components using anti-tumor necrosis factor and anti-IL-1 antibodies. J. Immunol.148:2133-2141.
18. DeForge LE, Remick DG. 1991. Kinetics of TNF, IL-6, and IL-8 geneexpression in LPS-stimulated human whole blood. Biochem. Biophys. Res. Commun. 174:18 -24.
19. de L Costello AM, et al. 1992. Does antibody to mycobacterial antigens,including lipoarabinomannan, limit dissemination in childhood tuberculosis?Trans. R. Soc. Trop. Med. Hyg. 86:686-692.
20. Evangelidou M, Tseveleki V, Vamvakas SS, Probert L. 2010. TNFRI is a positive T-cell costimulatory molecule important for the timing of cytokine responses. Immunol. Cell Biol. 88:586 -595.
21. Flynn JL, Chan J. 2001. Tuberculosis: latency and reactivation. Infect. Immun. 69:4195-4201.
22. Frishman JI, et al. 2000. Tumor necrosis factor (TNF)-alpha-induced interleukin-8 in human blood cultures discriminates neutralization by the p55 and p75 TNF soluble receptors. J. Infect. Dis. 182:1722-1730.
23. Hale KK, et al. 1995. Multifunctional regulation of the biological effects of TNF-alpha by the soluble type I and type II TNF receptors. Cytokine 7:26 -38.
24. Hamasur B, et al. 2001. Rapid diagnosis of tuberculosis by detection of mycobacterial lipoarabinomannan in urine. J. Microbiol. Methods 45:41-52.
25. Hamasur B, et al. 2004. A mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab=) fragment prolong survival of mice infected with Mycobacterium tuberculosis. Clin. Exp. Immunol. 138:30 -38.
26. Horton DL, Remick DG. 2010. Delayed addition of glucocorticoids selectively suppresses cytokine production in stimulated human whole blood. Clin. Vaccine Immunol. 17:979 -985.
27. Hwang C, Gatanaga M, Granger GA, Gatanaga T. 1993. Mechanism of release of soluble forms of tumor necrosis factor/lymphotoxin receptors by phorbol myristate acetate-stimulated human THP-1 cells in vitro. J.Immunol. 151:5631-5638.
28. Ilangumaran S, et al. 1995. Integration of mycobacterial lipoarabinomannans into glycosylphosphatidylinositol-rich domains of lymphomonocytic cell plasma membranes. J. Immunol. 155:1334 -1342.
29. Jeyanathan M, et al. 2008. Airway delivery of soluble mycobacterial antigens restores protective mucosal immunity by single intramuscular plasmidDNAtuberculosis vaccination: role of proinflammatory signals in thelung. J. Immunol. 181:5618 -5626.
30. Joyce DA, et al. 1994. Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes.Eur. J. Immunol. 24:2699 -2705.
31. Juffermans NP, et al. 1998. Tumor necrosis factor and interleukin-1 inhibitors as markers of disease activity of tuberculosis. Am. J. Respir. Crit.Care Med. 157:1328 -1331.
32. Kang PB, et al. 2005. The human macrophage mannose receptor directs Mycobacterium tuberculosis lipoarabinomannan-mediated phagosome biogenesis. J. Exp. Med. 202:987-999.
33. Keane J, et al. 2001. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 345:1098 -1104.
34. Khoo K-H, Tang J-B, Chatterjee D. 2000. Variation in mannose-capped terminal arabinan motifs of lipoarabinomannans from clinical isolates of Mycobacterium tuberculosis and Mycobacterium avium complex. J. Biol.Chem. 276:3863-3871.
35. Knight PR, et al. 2004. Development of a sensitive microarray immunoassay and comparison with standard enzyme-linked immunoassay for cytokine analysis. Shock 21:26 -30.
36. Kohno T, et al. 1990. A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor.Proc. Natl. Acad. Sci. U. S. A. 87:8331-8335.
37. Kumar V, Abbas AK, Fausto N, Mitchell R. 2007. Robbins basic pathology,8th ed, p 442-443, 518-522. Saunders Elsevier, Philadelphia, PA.
38. Mahon RN, et al. 2009. Mycobacterium tuberculosis cell wall glycolipids directly inhibit CD4 T-cell activation by interfering with proximal T-cellreceptor signaling. Infect. Immun. 77:4574-4583.
39. Majumder N, et al. 2006. An unusual pro-inflammatory role of interleukin-10 induced by arabinosylated lipoarabinomannan in murine peritoneal macrophages. Glycoc onj. J. 23:675-686.
40. Moreira AL, et al. 2002. Mycobacterial antigens exacerbate disease manifestations in Mycobacterium tuberculosis-infected mice. Infect. Immun.70:2100 -2107.
41. Moreno C, Mehlert A, Lamb J. 1988. The inhibitory effects of mycobacterial lipoarabinomannan and polysaccharides upon polyclonal and monoclonal human T cell proliferation. Clin. Exp. Immunol. 74:206 -210.
42. Natarajan S, Kim J, Remick DG. 2008. Acute pulmonary lipopolysaccharide tolerance decreases TNF-alpha without reducing neutrophil recruitment.J. Immunol. 181:8402-8408.
43. Nemzek JA, Siddiqui J, Remick DG. 2001. Development and optimization of cytokine ELISAs using commercial antibody pairs. J. Immunol.Methods 255:149 -157.
44. Pereira Arias-Bouda LM, et al. 2000. Development of antigen detection assay for diagnosis of tuberculosis using sputum samples. J. Clin. Microbiol.38:2278 -2283.
45. Qureshi HY, Ahmad R, Sylvester J, Zafarullah M. 2007. Requirement of phosphatidylinositol 3-kinase/Akt signaling pathway for regulation of tissue inhibitor of metalloproteinases-3 gene expression by TGF-beta in human chondrocytes. Cell. Signal. 19:1643-1651.
46. Roach DR, et al. 2002. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J. Immunol. 168:4620-4627.
47. Russell DG. 2007. Who puts the tubercle in tuberculosis? Nat. Rev. Microbiol.5:39-47.
48. Saunders BM, Cooper AM. 2000. Restraining mycobacteria: role of granulomas in mycobacterial infections. Immunol. Cell Biol. 78:334 -341.
49. Saunders BM, et al. 2005. Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not longterm, control of Mycobacterium tuberculosis infection. J. Immunol. 174:4852-4859.
50. Shabaana AK, et al. 2005. Mycobacterial lipoarabinomannans modulate cytokine production in human T helper cells by interfering with raft/microdomain signalling. Cell. Mol. Life Sci. 62:179 -187.
51. Strohmeier G, Fenton M. 1999. Roles of lipoarabinomannan in the pathogenesis of tuberculosis. Microbes Infect. 1:709 -717.
52. Tsakadze NL, et al. 2006. Tumor necrosis factor-alpha-converting enzyme (TACE/ADAM-17) mediates the ectodomain cleavage of intercellular adhesion molecule-1 (ICAM-1). J. Biol. Chem. 281:3157-3164.
53. Tsao TC, et al. 2000. Imbalances between tumor necrosis factor-alpha and its soluble receptor forms, and interleukin-1beta and interleukin-1 receptor antagonist in BAL fluid of cavitary pulmonary tuberculosis.Chest 117:103-109.
54. Ulich TR, et al. 1993. Intratracheal administration of endotoxin and cytokines. IV. The soluble tumor necrosis factor receptor type I inhibits acute inflammation. Am. J. Pathol. 142:1335-1338.
55. Winthrop KL, Siegel JN, Jereb J, Taylor Z, Iademarco MF. 2005.Tuberculosis associated with therapy against tumor necrosis factor alpha.Arthritis Rheum. 52:2968 -2974.
56. World Health Organization. 2008. Global tuberculosis control: surveillance,planning, financing. 2008 report. World Health Organization, Geneva,Switzerland.
57. Xin L, et al. 2006. Dual regulation of soluble tumor necrosis factor-alpha induced activation of human monocytic cells via modulating transmembrane TNF-alpha-mediated 'reverse signaling'. Int. J. Mol. Med. 18:885-892.
58. Xu P, Liu J, Sakaki-Yumoto M, Derynck R. 2012. TACE activation by MAPK-mediated regulation of cell surface dimerization and TIMP3 association. Sci. Signal. 5:ra34. doi:10.1126/scisignal.2002689.